Akouos IPO Presentation Deck

Key Advantages to Our Manufacturing Process 41 Well characterized HEK293 cell suspension and 250 L bioreactor system Potential to expand beyond Phase 1/2 Exclusive access to AAVAnc Vectors for inner ear provides opportunity to optimize production process and secure additional competitive advantage CONFIDENTIAL AKOUOS Low dose requirements given small size of the inner ear Targeted delivery and high transduction efficiency alleviate the need for large scale production

View entire presentation